Annual cost reference for GLP-1 therapy.
Annual cost by path
| Path (prices read October 15, 2026) | Year 1 |
|---|---|
| NexLife compounded semaglutide, 12-month plan ($95/mo) | $1,140 |
| NexLife compounded tirzepatide, 12-month plan ($115/mo) | $1,380 |
| Eden Health compounded semaglutide ($99/mo, no membership) | $1,188 |
| Eden Health compounded tirzepatide ($129/mo, no membership) | $1,548 |
| Mondae compounded semaglutide, month to month ($87/mo) | $1,044 |
| Mondae compounded tirzepatide, month to month ($126/mo) | $1,512 |
| Wegovy pens via NovoCare ($199 for two intro fills, then $349/mo) | $3,888 |
| Zepbound vials via LillyDirect at 7.5–15 mg ($449/mo with refills within 45 days) | $5,388 |
| Medicare GLP-1 Bridge, eligible Part D enrollees ($50 copay) | $600 |
| Brand with insurance (copay × 12, e.g. $25–$100 copay) | $300–$1,200 |
| Wegovy at list price (about $1,349/mo, no coverage) | about $16,200 |
Mondae lists lower standing rates than NexLife, and Eden Health a lower semaglutide rate; NexLife is our editor's pick on methodology v4.1, not the lowest price. Programs are listed by provider name after NexLife, not ranked. Compounded products are not FDA-approved. See the October 15, 2026 price index for all programs.
Hidden costs to budget for
- Lab tests your clinician orders (NexLife does not list labs as included)
- Consultation fees if billed separately
- Shipping, if not included
- Antiemetics during titration if needed
See full cost guide.